Allergan CEO Brent Saunders weighs in on Trump’s first month: 4 key notes

Parsippany-Troy Hills, N.J.-based Allergan CEO Brent Saunders gave his take to Fox News on President Donald Trump’s first month in office.

Advertisement

Here’s what you should know.

1. Mr. Saunders said President Trump is a “populist first” politician, that is also pro-growth and pro-innovation.

2. Concerning companies outsourcing work or relocating out of the country, Mr. Saunders said President Trump is taking a different approach from former President Barack Obama. He told Fox, “[Trump is] saying ‘no, let’s fix our problems so you don’t want to leave. Let’s go to a more territorial based tax system and make American companies more competitive globally.'”

3. Despite campaign promises to reduce corporate taxes, Mr. Saunders said Allergan wouldn’t move its operations from Ireland.

4. President Trump wants to lower drug prices. Although Mr. Saunders said lowering prices is a good thing, he believes the industry should address pricing, not the government.

More articles on improving health:
7 things for ASC leaders to know for Thursday — Feb. 23, 2017
Physician engagement through professional development: Q&A with Sheridan Chief Quality Officer Dr. Gerald Maccioli
Tenet shares plummet 18.7% in 52-week period: 4 points

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in ASC News

  • Health systems are putting more capital into ASCs in 2026, through billion-dollar acquisitions, multisite joint ventures and single-site builds. The…

  • ASC development is accelerating across the Southeast as demographic, economic and regulatory pressures converge, Brian Blankenship, vice president of project…

Advertisement

Comments are closed.